NYSE · Healthcare · Medical Instruments & Supplies · USA
Envista Holdings Corp is a mid cap company (market value between $2 billion and $10 billion) in the Medical Instruments & Supplies industry.
Envista is a global dental products company comprising multiple brands including Nobel Biocare, Ormco, DEXIS, and Kerr. It develops and markets dental implants, orthodontic solutions, digital imaging systems, and consumable products serving dental professionals worldwide through direct sales and distribution partners across two segments: Specialty Products & Technologies and Equipment & Consumables.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Envista Holdings Corp stock.
Overvalued: intrinsic value $13.84 per share, market price $22.97, margin of safety -65.9% (as of 2026-10-20).
Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $13.84; the price of $22.97 is 66% above that value, and 77% of that value comes from beyond year five.
Leak Score: 44/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 50 Medical Instruments & Supplies stocks
11 more in this industry show a wider margin of safety.
NVST is overvalued (as of the 2026-10-20 close). Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $13.84; the price of $22.97 is 66% above that value, and 77% of that value comes from beyond year five.
$13.84 per share (as of the 2026-10-20 close), against a market price of $22.97. That is a margin of safety of -65.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
44 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.